Serum levels of sFAS and sFasL during chemotherapy of lung cancer

Experimental Oncology

Volumn 29, Issue 2, 2007, Pages 132-136

  Naumnik, W ^a   Izycki, T ^a   Ossolinska M ^a   Chyczewska, E ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Chemotherapy; Non small cell lung cancer; Small cell lung cancer; Soluble Fas; Soluble Fas ligand

Indexed keywords

ANTINEOPLASTIC AGENT; FAS ANTIGEN; FAS LIGAND;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PROTEIN BLOOD LEVEL; PROTEIN STABILITY; SOLUBILITY; TREATMENT RESPONSE;

ADULT; AGED; ANTIGENS, CD95; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SOLUBILITY;

EID: 34548160470     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Akhmedkhanov A, Lundin E, Guller S, Lukanova A, Micheli A, Ma Y, Afanasyeva Y, Zeleniuch-Jacquotte A, Krogh V, Lenner P, Muti P, Rinaldi S, Kaaks R, Berrino F, Hallmans G, Toniolo P. Circulating soluble Fas levels and risk of ovarian cancer. BMJ Cancer 2003; 3: 33.
2. von Bernstorff W, Spanjaard RA, Chan AK, Lockhart DC, Sadanaga N, Wood I, Peiper M, Goedegebuure PS, Eberlein TJ. Pancreatic cancer cells can evade immune surveillance via non-functional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand. Surgery 1999; 125: 73-84.
3. Enjoji M, Yamaguchi K, Nakashima M, Ohta S, Kotoh K, Fukushima M, Kuniyoshi M, Tanaka M, Nakamuta M, Watanabe T, Nawata H. Serum levels of soluble molecules associated with evasion of immune surveillance: a study in biliary disease. Liver Int 2004; 24: 330-4.
4. Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 1998; 58: 2057-62.
5. Ichikura T, Majima T, Uchida T, Okura E, Ogawa T, Mochizuki H. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma. Oncol Rep 2001; 8: 311-4.
6. Jodo S, Kobayashi S, Nakajima Y, Matsunaga T, Nakayama N, Ogura N, Kayagaki N, Okumura K, Koike T. Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol 1998; 112: 166-71.
7. Kimura M, Tomita Y, Imai T, Saito T, Katagiri A, Tanikawa T, Takeda M, Takahashi K. Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients. Br J Cancer 1999; 80: 1648-51.
8. Knipping E, Debatin KM, Stricker K, Heilig B, Eder A, Krammer PH. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemia. Blood 1995; 85: 1562-9.
9. Kondera-Anasz Z, Mielczarek-Palacz A, Sikora J. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors. Apoptosis 2005; 10: 1143-9.
10. Melzani G, Bugari G, Parrinello G, Mori G, Manganoni AM, De Panfilis G. Evaluation of soluble Fas ligand as a serological marker for melanoma. Dermatology 2002; 205: 111-5.
11. Micheau O, Solary E, Hammann A, Martin F, Dimanche-Boitrel MT. Sensitization of cancer cells treated with cytotoxic drugs to Fas-mediated cytotoxicity. J Natl Cancer Inst 1997; 89: 783-9.
12. Midis GP, Shen Y, Owen-Schaub LB. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res 1996; 56: 3870-4.
13. Mouawad R, Khayat D, Soubrane C. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma. Melanoma Res 2000; 10: 461-7.
14. Murakami M, Sasaki T, Miyata H, Yamasaki S, Kuwahara K, Chayama K. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma. Oncol Rep 2004; 11: 1183-6.
15. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-65.
16. Nonomura N, Nishimura K, Ono Y, Fukui T, Harada Y, Takaha N, Takahara S, Okuyama A. Soluble Fas in serum from patients with renal cell carcinoma. Urology 2000; 55: 151-5.
17. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-82.
18. Owen-Schaub LB, Angelo LS, Radinsky R, Ware CF, Gesner TG, Bartos DP. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett 1995; 94: 1-8.
19. Shimizu M, Kondo M, Ito Y, Kume H, Suzuki R, Yamaki K. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients. Cancer Detect Prev 2005; 29: 175-80.
20. Tanaka M, Suda T, Takahashi T, Nagata S. Expression of the functional soluble form of human ligand in activated lymphocytes. EMBO J 1995; 14: 1129-35.
21. Ueno T, Toi M, Tominaga T. Circulating soluble Fas concentration in breast cancer patients. Clin Cancer Res 1999; 5: 3529-33.
22. Walker PR, Saas P, Dietrich PY. Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back. J Immunol 1997; 158: 4521-4.
23. Yoshimura C, Nomura S, Kanazawa S, Kuwana M, Muramatsu M, Yamaguchi K, Fukuhara S. Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2. J Cancer Res Clin Oncol 2002; 128: 581-8.